News Headlines

  1. RoosterBio Announces Collaboration With Thermo Fisher Scientific To Advance Cell & Exosome Therapy Manufacturing 4/29/2025

    RoosterBio, Inc., a leading supplier of adult human mesenchymal stem/stromal cells (hMSCs), highly engineered media, and bioprocess development services, today announced a new collaboration with Thermo Fisher Scientific, the world leader in serving science.

  2. PCI Pharma Services To Acquire US-based Aseptic Fill-Finish CDMO Ajinomoto Althea 4/24/2025

    PCI Pharma Services (“PCI”) – a leading global contract development and manufacturing organization (CDMO) focused on innovative biopharma therapies – is acquiring an entire equity stake in Ajinomoto Althea, Inc. (“Althea”), a US-based sterile fill-finish CDMO and 100% subsidiary of Japan-based Ajinomoto Co., Inc. Scheduled for completion in May 2025, the acquisition provides PCI with its first-ever North American manufacturing location for prefilled syringes and cartridges – including isolator technology for these formats – as well as high potent manufacturing suitable for antibody-drug conjugates (ADCs).

  3. Tyber, Intech & Resolve Finalize Merger To Form Global CDMO+ For Musculoskeletal Device Solutions 4/24/2025

    In a pivotal move shaping the future of MedTech, Tyber Medical, Intech, and Resolve Surgical Technologies have merged into a unified, leading developer, designer and manufacturer of surgical devices focused on serving the needs of MedTech OEMs and patients.

  4. Pentixapharm Signs Contract Manufacturing Agreement For Yttrium-90-Based PentixaTher With Eckert & Ziegler SE 4/24/2025

    Pentixapharm, a clinical-stage biopharmaceutical company, today announced the signing of a manufacturing agreement with Eckert & Ziegler Radiopharma GmbH (EZR), a 100% subsidiary of Eckert & Ziegler SE. Under the terms of the agreement, EZR will produce and distribute patient-specific doses of Y90-PentixaTher, Pentixapharm’s lead CXCR4-targeting radiotherapeutic, for use in clinical trials.

  5. Evotec Announces Significant Progress In Strategic Protein Degradation Collaboration With Bristol Myers Squibb 4/24/2025

    Evotec SE today announced further significant progress of the Company’s strategic research collaboration with Bristol Myers Squibb relating to building a high value molecular glue-based pipeline for unmet medical needs.

  6. ITM And Alpha-9 Oncology Enter Into Supply Agreement For Therapeutic Medical Radioisotope Actinium-225 4/24/2025

    ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Alpha-9 Oncology (Alpha-9), a clinical-stage biotechnology company advancing a distinctive portfolio of differentiated and highly targeted radiopharmaceuticals, today announced the signing of a supply agreement for Actinium-225 (Ac-225) to support the development of Alpha-9’s radiopharmaceutical programs.

  7. Meridian Bioscience Introduces New Enzyme Stabilization Services For Molecular Diagnostics 4/23/2025

    The Life Science division of Meridian Bioscience, Inc., a leading global manufacturer of diagnostics and life science raw materials, today announced the expansion of its contract services, enabling assay developers working with qPCR, isothermal amplification, or next-generation sequencing (NGS) technologies to achieve enhanced assay stability, lower limits of detection (LOD), and improved cost efficiencies through Meridian's advanced enzyme stabilization technologies.

  8. Silexion Therapeutics Announces Collaboration With Global Therapeutics Leader Catalent On Advanced siRNA Formulation Development & Clinical Manufacturing Activities 4/23/2025

    Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a strategic collaboration with Catalent, a global leader in advanced delivery technologies, clinical development, and manufacturing solutions for therapeutics.

  9. LOTTE BIOLOGICS Begins Full-Scale Operation Of ADC Manufacturing Facility 4/23/2025

    LOTTE BIOLOGICS (CEO James Park) announced on April 24 (KST) that it has signed a manufacturing agreement with an Asia-based biotech company for the production of a clinical-stage ADC candidate.

  10. Phlow Corp. Expands Analytical Capabilities And Embraces Artificial Intelligence-Driven System, Ushering In A New Era Of Modern Medicine Manufacturing In America 4/22/2025

    Phlow Corp., a leading pharmaceutical contract development and manufacturing organization (CDMO) in America, announced today a significant expansion in its analytical capabilities, use of artificial intelligence (AI), workforce, and domestic infrastructure.